Marshall Wace’s ADMA Biologics ADMA Stock Holding History

Marshall Wace’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Buy	+307,254	New	+$2.8M	﹤0.01%	1714
2025 Q3	–	Sell	-21,090	Closed	-$384K	–	2842
2025 Q2	$384K	Buy	+21,090	New	+$430K	﹤0.01%	2235
2024 Q3	–	Sell	-26,800	Closed	-$300K	–	2449
2024 Q2	$300K	Buy	26,800 +8,203	+44%	+$68.8K	﹤0.01%	2158
2024 Q1	$123K	Buy	+18,597	New	+$102K	﹤0.01%	2289
2023 Q4	–	Sell	-143,479	Closed	-$514K	–	2121
2023 Q3	$514K	Buy	+143,479	New	+$552K	﹤0.01%	1717
2023 Q2	–	Sell	-114,900	Closed	-$380K	–	2409
2023 Q1	$380K	Buy	+114,900	New	+$397K	﹤0.01%	2215
2021 Q1	–	Sell	-2,490,900	Closed	-$4.86M	–	2418
2020 Q4	$4.86M	Hold	2,490,900	–	–	0.03%	590
2020 Q3	$5.95M	Buy	2,490,900 +1,581,974	+174%	+$4.34M	0.04%	460
2020 Q2	$2.66M	Buy	908,926 +46,534	+5%	+$134K	0.02%	685
2020 Q1	$2.48M	Buy	+862,392	New	+$2.98M	0.02%	558

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace's ADMA Position: Q2 2026 in Review

Marshall Wace opened a new position in ADMA Biologics (ADMA) in Q2 2026: 307,254 shares worth $2.57M. The stake represents ﹤0.01% of the portfolio and ranks #1714 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ADMA as recently as Q2 2025.

Marshall Wace first reported a position in ADMA in Q1 2020 and has held it in 10 quarters since. The position peaked at $5.95M in Q3 2020. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Marshall Wace held 307,254 shares of ADMA Biologics worth $2.57M as of Q2 2026.
ADMA Biologics was a new Marshall Wace position in Q2 2026.
ADMA Biologics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1714 holding.
Marshall Wace first reported a position in ADMA Biologics in Q1 2020 and has held it in 10 quarters since.
Marshall Wace's ADMA Biologics position peaked at $5.95M in Q3 2020.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.